Apolipoprotein B-48: A unique marker of chylomicron metabolism

Advances in Clinical Chemistry

Volumn 64, Issue , 2014, Pages 117-177

  Nakajima, Katsuyuki ^a,b,d,e   Nagamine, Takeaki ^a   Fujita, Masaki Q ^b   Ai, Masumi ^c,d   Tanaka, Akira ^d   Schaefer, Ernst ^e  

^a GUNMA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KAGAWA NUTRITION UNIVERSITY   (Japan)

^e TUFTS UNIVERSITY   (United States)

Author keywords

ApoB 100; ApoB 48; Chylomicron remnants; Postprandial lipoproteins; Remnant lipoprotein particles; Very low density lipoprotein remnants

Indexed keywords

APOLIPOPROTEIN B48; BIOLOGICAL MARKER; CHYLOMICRON; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL; BLOOD; CIRCADIAN RHYTHM; DEATH, SUDDEN, CARDIAC; GENE THERAPY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; RNA EDITING;

ANIMALS; APOLIPOPROTEIN B-48; BIOLOGICAL MARKERS; CHYLOMICRONS; CIRCADIAN RHYTHM; DEATH, SUDDEN, CARDIAC; GENETIC THERAPY; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; RNA EDITING; TRIGLYCERIDES;

EID: 84897938969     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800263-6.00003-3     Document Type: Chapter

References (218)

1. Havel R.J. Postprandial hyperlipidemia and remnant lipoproteins. Curr. Opin. Lipidol. 1994, 5:102-109.
2. Havel R.J. Remnant lipoproteins as therapeutic targets. Curr. Opin. Lipidol. 2000, 11:615-620.
3. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 2001, 153:490-499.
4. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
5. Bansal S., Buring J., Rifai N., Mora S., Sacks F.M., Rider P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
6. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
7. Fojo S.S., Brewer H.B. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J. Intern. Med. 1992, 23:669-677.
8. Demacker P.N., Bredie S.J., Vogelaar J.M., Hectors M.P., van Heijst P., Stuyt P.M., et al. Beta-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins. Atherosclerosis 1998, 138:301-312.
9. Meng M.S., Gregg R.E., Schaefer E.J., Hoeg J.M., Brewer H.B. Presence of two forms of apolipoprotein B in patients with dyslipoproteinemia. J. Lipid Res. 1983, 24:803-809.
10. Kane J.P., Chen G.C., Hamilton R.L., Hardman D.A., Malloy M.J., Havel R.J. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis 1983, 3:47-56.
11. Haffner S.M., Kushwaha R.S., Hazzard W.R. Metabolism of chylomicrons in subjects with dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Eur. J. Clin. Invest. 1989, 19:486-490.
12. Cohn J.S., Johnson E.J., Millar J.S., Cohn S.D., Milne R.W., Marcel Y.L., et al. Contribution of apoB-48and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J. Lipid Res. 1993, 34:2033-2040.
13. Kane J.P. The lipoproteins in human serum. Lipid Metabolism in Mammals 1977, 209-257. Plenum, New York. F. Snyder (Ed.).
14. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gel. Clin. Chim. Acta 1993, 223:53-71.
15. Nakajima K., Okazaki M., Tanaka A., Nakano T., Adachi M., Pullinger C.R., et al. Separation and determination of remnant-like particles in serum from diabetes patients using monoclonal antibodies to apo B-100 and apo A-I. J. Clin. Ligand Assay 1996, 19:177-183.
16. Okazaki M., Usui S., Hosaki S. Analysis of plasma lipoproteins bygel permeation chromatography. Handbook of Lipoprotein Testing 2000, 647-669. AACC Press, Washington, DC. N. Rifai, G.R. Warnick, M.H. Dominiczak (Eds.).
17. Kinoshita M., Kojima M., Matsushima T., Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin. Chim. Acta 2005, 351:115-120.
18. Morrisett J.D., Jackson R.L., Gotto A.M. Lipoproteins: structure and function. Annu. Rev. Biochem. 1975, 44:183-207.
19. Innerarity T.L., Mahley R.W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978, 17:1440-1447.
20. Socorro L., Camejo G. Preparation and properties of soluble, immunoreactive apoLDL. J. Lipid Res. 1979, 20:631-638.
21. Kane J.P., Hardman D.A., Paulus H.E. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc. Natl. Acad. Sci. U.S.A. 1980, 77:2465-2469. (lipoproteins/protein moiety/lipid transport).
22. Chen C.-H., Aladjem F. Further studies on the subunit structure of human serum low density lipoproteins. Biochem. Med. 1978, 19:178-187.
23. Steele J.C.H., Reynolds J.A. Molecular weight and hydrodynamic properties of apolipoprotein B in guanidine hydrochloride and sodium dodecyl sulfate solutions. J. Biol. Chem. 1979, 254:1639-1643.
24. Steele J.C.H., Reynolds J.A. Characterization of the apolipoprotein B polypeptide of human plasma low density lipoprotein in detergent and denaturation solutions. J. Biol. Chem. 1979, 254:1633-1638.
25. Chapman M.J., Kane J.P. Stability of the apoprotein of human serum low density lipoprotein: absence of endogenous endopeptidase activity. Biochem. Biophys. Res. Commun. 1975, 66:1030-1036.
26. Young S.G. Recent progress in understanding apolipoprotein B. Circulation 1990, 82:1574-1594.
27. Herz J., Willnow T.E. Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipidol. 1995, 6:97-103.
28. Hussain M.M., Strickland D.K., Bakillah A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19:141-172.
29. Powell L.M., Wallis S.C., Pease R.J., et al. A novel form of tissue-specific RNA processin produces apolipoprotein-B48 in intestine. Cell 1987, 50:831-840.
30. Chen S.H., Habib G., Yang C.Y., Gu Z.W., Lee B.R., Weng S.A., et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987, 238:363-366.
31. Harris S.G., Sabio I., Mayer E., Steinberg M.F., Backus J.W., Sparks J.D., et al. Extractspecific heterogeneity in high-order complexes containing apolipoprotein B mRNA editing activity and RNA-binding proteins. J. Biol. Chem. 1993, 268:7382-7392.
32. Black D.D. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G519-G524.
33. Tso P., Liu M. Apolipoprotein A-IV, food intake, and obesity. Physiol. Behav. 2004, 83:631-643.
34. Siddiqi S.A., Siddiqi S., Mahan J., Peggs K., Gorelick F.S., Mansbach C.M. The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle. J. Biol. Chem. 2006, 281:20974-20982.
35. Neeli I., Siddiqi S.A., Siddiqi S., Mahan J., Lagakos W.S., Binas B., et al. Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. J. Biol. Chem. 2007, 282:17974-17984.
36. Nakajima K., Nakano T., Tokita Y., Nagamine T., Inazu A., Kobayashi J., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin. Chim. Acta 2011, 412:1306-1318.
37. Hayashi H., Fujimoto K., Cardelli J.A., Nutting D.F., Bergstedt S., Tso P. Fat feeding increases size, but not number of, chylomicrons produced by small intestine. Am. J. Physiol. 1990, 259:709-719.
38. Martins I.J., Sainsbury A.J., Mamo J.C.L., Redgrave T.G. Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia 1994, 37:238-246.
39. Vinge J.L., Havel R.J. Metabolism of apolipoprotein A-I of chylomicrons in rats and humans. Can. J. Biochem. 1981, 59:613-619.
40. Patsch J. Postprandial lipaemia. Bailliere's Clin. Endocrinol. Metab. 1987, 1:551-580.
41. Zeng B.J., Mortimer B.C., Martins I.J., Seydel U., Redgrave T.G. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 1998, 39:845-860.
42. Grundy S.M., Mok M.Y.I. Chylomicron clearance in normal and hyperlipoproteinemic subjects. Metabolism 1976, 25:1225-1239.
43. Karpe F., Olivecrona T., Hamsten A., Hultin M. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J. Lipid Res. 1997, 38:949-961.
44. Bjorkegren J., Packard C.J., Hamsten A., Bedford D., Caslake M., Foster L., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid Res. 1996, 37:76-86.
45. Karpe F., Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J. Lipid Res. 1995, 36:1557-1566.
46. Karpe F., HelleÂnius M.-L., Hamsten A. Differences in postprandial concentrations of very low density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary artery disease. Metabolism 1999, 48:301-307.
47. Karpe F. Postprandial lipoportein metabolism and atherosclerosis. J. Intern. Med. 1999, 246:341-355.
48. Semb H., Olivecrona T. Nutritional regulation of lipoprotein lipase in guinea pig tissue. Biochim. Biophys. Acta 1986, 876:249-255.
49. Ong J.M., Kern P.A. Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J. Clin. Invest. 1989, 84:305-311.
50. Frayn K.N., Shadid S., Hamlani R., Humphreys S.M., Clark M.L., Fielding B.A., et al. Regulation of fatty acid movement in human adipose tissue in the postabsorbtive-topostprandial transition. Am. J. Physiol. 1994, 266:E308-E317.
51. Nakajima K., Kobayashi J., Mabuchi H., Nakano T., Tokita Y., Nagamine T., et al. Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma. Ann. Clin. Biochem. 2010, 47:423-431.
52. Murase T., Itakura H. Accumulation of intermediate density lipoprotein in plasma after intravenous administration of hepatic triglyceride lipase antibody in rats. Atherosclerosis 1981, 39:293-300.
53. Goldberg I.J., Le N.A., Paterniti J.R., Ginsberg H.N., Lindgren F.T., Brown W.V. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J. Clin. Invest. 1982, 70:1184-1192.
54. Oi K., Hirano T., Sakai S., Kawaguchi Y., Hosoya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int. Suppl. 1999, 71:S227-S228.
55. Zambon A., Deeb S.S., Pauletto P., Crepaldi G., Brunzell J.D. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr. Opin. Lipidol. 2003, 14:179-189.
56. Deeb S.S., Zambon A., Carr M.C., Ayyobi A.F., Brunzell J.D. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J. Lipid Res. 2003, 44:1279-1286.
57. Eisenberg S. Remnant lipoprotein metabolism. Diabetes, Obesity and Hyperlipidemia: V. The Plurimetabolic Syndrome 1993, 7-14. Elsevier Science Publishers, New York, NY. G. Crepaldi, A. Tiengo, E. Manzato (Eds.).
58. Mjøs O.D., Faergeman O., Hamilton R.L., Havel R.J. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J. Clin. Invest. 1975, 56:603-615.
59. Pagnan A., Havel R.J., Kane J.P., Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J. Lipid Res. 1977, 18:613-622.
60. Chung B.H., Segrest J.P., Smit K., Griffin F.M., Brouillette C.G. Lipolytic surface remnant of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis. J. Clin. Invest. 1989, 83:1363-1374.
61. Goldstein J.L., Ho Y.K., Brown M.S., Innerarity T.L., Mahley R.W. Cholesterol ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J. Biol. Chem. 1980, 255:1839-1848.
62. Cohn J.S., Davignon J. Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants. Atherosclerosis XI 1998, 771-776. Elsevier Science, Singapore. B. Jacotot, D. Mathé, J.C. Fruchart (Eds.).
63. Brown M.L., Ramprasad M.P., Umeda P.K., Tanaka A., Kobayashi Y., Watanabe T., et al. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7488-7493.
64. Gianturco S.H., Ramprasad M.P., Song R., Li R., Brown M.L., Bradley W.A. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocytemacrophage receptor. Arterioscler. Thromb. Vasc. Biol. 1998, 18:968-976.
65. Hussain M.M., Mahley R.W., Boyles J.K., Fainaru M., Brecht W.J., Lindquist P.A. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. J. Biol. Chem. 1989, 264:9571-9582.
66. Haraguchi G., Kobayashi Y., Brown M.L., Tanaka A., Isobe M., Gianturco S.H., et al. PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. J. Lipid Res. 2003, 44:1224-1231.
67. Kawakami A., Tani M., Chiba T., Yui K., Shinozaki S., Nakajima K., et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 2005, 25:424-429.
68. Gianturco S.H., Lin A.H., Hwang S.L., Young J., Brown S.A., Via D.P., et al. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J. Clin. Invest. 1988, 82:1633-1643.
69. Gianturco S.H., Ramprasad M.P., Lin A.H., Song R., Bradley W.A. Cellular binding site and membrane binding proteins for triglyceride-rich ipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J. Lipid Res. 1994, 35:1674-1687.
70. Bermudez B., Lopez S., Varela L.M., Ortega A., Pacheco Y.M., Moreda W., et al. Triglyceride-rich lipoprotein regulates APOB48 receptor gene expression in human THP-1 monocytes and macrophages. J. Nutr. 2012, 142:227-232.
71. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
72. Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:5810-5814.
73. Nestel P.J. Relationship between plasma triglycerides and removal of chylomicrons. J. Clin. Invest. 1964, 43:943-949.
74. Grundy S.M., Mok H.Y. Chylomicron clearance in normal and hyperlipidemic man. Metabolism 1976, 25:1225-1239.
75. Nestel P.J., Billington T., Fidge N.H. Slower removal of intestinal apolipoprotein B-48 than of apolipoprotein B-100 in severely hypertriglyceridemic subjects. Biochim. Biophys. Acta 1983, 751:422-427.
76. Stalenhoef A.F., Malloy M.J., Kane J.P., Havel R.J. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:1839-1843.
77. Lichtenstein A.H., Hachey D.L., Millar J.S., Jenner J.L., Booth L., Ordovas J., et al. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5, 5,5-2H3]leucine. J. Lipid Res. 1992, 33:907-914.
78. Schaefer E.J. E.V. McCollum Award Lecture: lipoproteins, nutrition, and heart disease. Am. J. Clin. Nutr. 2002, 75:191-212.
79. Nakajima K., Nakano T., Moon H.D., Nagamine T., Stanhope K.L., Havel P.J., et al. The correlation between TG vs remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers. Clin. Chim. Acta 2009, 404:124-127.
80. Stanhope K.L., Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 2009, 119:1322-1334.
81. Lapice E., Cipriano P., Patti L., Romano G., Vaccaro O., Rivellese A.A. Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study. Atherosclerosis 2012, 223:504-506.
82. Mifflin M.D., St Jeor S.T., Hill L.A., Scott B.J., Daugherty S.A., Koh Y.O. A new predictive equation for resting energy expenditure in healthy individuals. Am. J. Clin. Nutr. 1990, 51:241-247.
83. Ooi T.C., Cousins M., Ooi D.S., Steiner G., Uffelman K.D., Nakajima K., et al. Postprandial remnant- like lipoproteins in hypertriglyceridemia. J. Clin. Endocrinol. Metab. 2001, 86:3134-3142.
84. Ai M., Tanaka A., Ogita K., Sekinc M., Numano F., Numano F., et al. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J. Am. Coll. Cardiol. 2001, 38:1628-1632.
85. Sekihara T., Nakano T., Nakajima K. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis. Jpn. J. Nephrol. 1996, 38:220-228.
86. Nakano T., Tanaka A., Okazaki M., Tokita Y., Nagamine T., Nakajima K. Particle size of apoB-48 carrying lipoproteins in remnant lipoproteins isolated from postprandial plasma. Ann. Clin. Biochem. 2011, 48:57-64.
87. Tanaka A., Tomie N., Nakano T., Nakajima K., Yui K., Tamura M., et al. Measurement of postprandial remnant-like particles (RLP) following a fat-loading test. Clin. Chim. Acta 1998, 275:43-52.
88. Masuda D., Sakai N., Sugimoto T., Kitazume-Taneike R., Yamashita T., Kawase R., et al. Fasting serum apolipoprotein B-48 Can be a marker of postprandial hyperlipidemia. J. Atheroscler. Thromb. 2011, 22:1062-1070.
89. Inazu A., Nakajima K., Nakano T., Niimi M., Kawashiri M.A., Nohara A., et al. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis 2008, 196:953-957.
90. Dubois C., Armand M., Mekki N., Portugal H., Pauli A.M., Bernard P.M., et al. Effects of increasing amounts of dietary cholesterol on postprandial lipemia and lipoproteins in human subjects. Am. J. Clin. Nutr. 1994, 60:374-382.
91. Dubois C., Armand M., Ferezou J., Beaumier G., Portugal H., Pauli A.M., et al. Postprandial appearance of dietary deuterated cholesterol in the chylomicron fraction and whole plasma in healthy subjects. Am. J. Clin. Nutr. 1996, 64:47-52.
92. Marcoux C., Tremblay M., Fredenrich A., Jacques H., Krimbou L., Nakajima K., et al. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis 1998, 139:161-171.
93. Marcoux C., Tremblay M., Nakajima K., Davignon J., Cohn J.S. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J. Lipid Res. 1999, 40:636-647.
94. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay. J. Atheroscler. Thromb. 1994, 1:30-36.
95. Leary E.T., Wang T., Baker D.J., Cilla D.D., Zhong J., Warnick G.R., et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particlecholesterol in serum and plasma. Clin. Chem. 1998, 44:2490-2498.
96. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin. Chem. 1998, 44:1224-1232.
97. Campos E., Nakajima K., Tanaka A., Havel R.J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoprotein isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J. Lipid Res. 1992, 33:369-380.
98. Wang T., Nakajima K., Leary E.T., Warnick G.R., Cohn J.S., Hopkins P.N., et al. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia. Clin. Chem. 1999, 45:1981-1987.
99. Karpe F., Boquist S., Tang R., Bond G.M., de Faire U., Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J. Lipid Res. 2001, 42:17-21.
100. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
101. Twickler T.B., Dallinga-Thie G.M., Cohn J.S., Chapman M.J. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004, 109:1918-1925.
102. Nakajima K., Nakano T., Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin. Chim. Acta 2006, 367:36-47.
103. Lovegrove J.A., Isherwood S.G., Jackson K.G., Williams C.M., Gould B.J. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim. Biophys. Acta 1996, 1301:221-229.
104. Peel A.S., Komanduri P., Williams C.M., Morgan L.M., Gould B.J. A specific antibody to apolipoprotein B-48: a novel approach. Biochem. Soc. Trans. 1992, 20:165S.
105. Uchida Y., Kurano Y., Ito S. Establishment of monoclonal antibody against human apo B-48 and measurement of apoB-48 in serum by ELISA method. J. Clin. Lab. Anal. 1998, 12:89-292.
106. Sakai N., Uchida Y., Ohashi K., Hibuse T., Saika Y., Tomari Y., et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J. Lipid Res. 2003, 44:1256-1262.
107. Yao Z., Blackhart B.D., Linton M.F., Taylor S.M., Young S.G., McCarty B.J. Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat hepatoma cells. J. Biol. Chem. 1991, 266:3300-3308.
108. Otokozawa S., Ai M., Diffenderfer M.R., Asztalos B.F., Tanaka A., Lamon-Fava S., et al. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism 2009, 58:1536-1542.
109. Nakano T., Nakajima K., Niimi M., Fujita M.Q., Nakajima Y., Takeichi S., et al. Determination of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin. Chim. Acta 2008, 390:38-43.
110. Hara I., Okazaki M. High-performance liquid chromatography of serum lipoproteins. Methods Enzymol. 1986, 129:57-78.
111. Usui S., Nakamura M., Jitsukata K., Nara M., Hosaki S., Okazaki M. Assessment of between-instrument variations in a HPLC method for serum lipoproteins and its traceability to reference methods for total cholesterol and HDL-cholesterol. Clin. Chem. 2000, 46:63-72.
112. Usui S., Hara Y., Hosaki S., Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 2002, 43:805-814.
113. Okazaki M., Usui S., Ishigami M., Sakai N., Nakamura T., Matsuzawa Y., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol. 2005, 25:578-584.
114. Nakajima K., Nakano T., Tokita Y., Nagamine T., Yatsuzuka S., Shimomura Y., et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma. Clin. Chim. Acta 2012, 413:1077-1086.
115. Schneeman B.O., Kotite L., Todd K.M., Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoprotein B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:2069-2073.
116. Phillips N.R., Waters D., Havel R. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
117. Yoshimura N., Kinoshita M., Teramoto T. Isolation and characterization of apolipoprotein B48-containing lipoproteins with a monoclonal antibody against apolipoprotein B48. J. Atheroscler. Thromb. 2009, 16:740-747.
118. Valdivielso P., Puerta S., Rioja J., Alonso I., Ariza M.J., Sánchez-Chaparro M.A., et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. Clin. Chim. Acta 2010, 411:433-437.
119. Rivellese A.A., De Natale C., Di Marino L., Patti L., Iovine C., Coppola S., et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J. Clin. Endocrinol. Metab. 2004, 89:2153-2159.
120. Phillips M.L., Pullinger C., Kroes I., Kroes J., Hardman D.A., Chen G., et al. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J. Lipid Res. 1997, 38:1170-1177.
121. Smith D., Watts G.F., Dane-Stewart C., Mamo J.C. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur. J. Clin. Invest. 1999, 29:204-209.
122. Nakatani K., Sugimoto T., Masuda D., Okano R., Oya T., Monden Y., et al. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 2011, 218:226-232.
123. Brevetti G., Piscione F., Cirillo P., Galasso G., Schiano V., Barbato E., et al. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis 2008, 201:440-446.
124. Tanimura K., Nakajima Y., Nagao M., Ishizaki A., Kano T., Harada T., et al. Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2008, 81:338-344.
125. Mero N., Malmström R., Steiner G., Taskinen M.R., Syvänne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000, 150:167-177.
126. Karpe F., de Faire U., Mercuri M., Bond M.G., Hellénius M.L., Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 1998, 141:307-314.
127. Sakai N., Sugimoto T., Tsujii K. Fasting serum apolipoprotein (apo) B-48 levels measured by a novel ELISA are a simple and useful marker for postprandial hyperlipidemia and predict coronary heart disease (CHD). Circulation 2004, 110(Suppl. III). III-183.
128. Flood C., Gustafsson M., Richardson P.E., Harvey S.C., Segrest J.P., Borén J. Identification of the proteoglycan binding site in apolipoprotein B48. J. Biol. Chem. 2002, 277:32228-32233.
129. Fujioka Y., Cooper A.D., Fong L.G. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J. Lipid Res. 1998, 39:2339-2349.
130. Proctor S.D., Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1595-1600.
131. Pal S., Semorine K., Watts G.F., Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin. Chem. Lab. Med. 2003, 41:792-795.
132. Campos H., Khoo C., Sacks F.M. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis 2005, 181:345-351.
133. Chan D.C., Wong A.T., Yamashita S., Watts G.F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012, 221:484-489.
134. Maggi F.M., Raselli S., Grigore L., Redaelli L., Fantappiè S., Catapano A.L. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J. Clin. Endocrinol. Metab. 2004, 89:2946-2950.
135. Nakamura T., Takano H., Umetani K., Kawabata K., Obata J.E., Kitta Y., et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181:321-327.
136. Valero R., Lorec A.M., Paganelli F., Beliard S., Atlan C., Lairon D., et al. Fasting apoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia. Metabolism 2005, 54:1442-1447.
137. De Silva H.V., Lauer S.J., Wang J., Simonet W.S., Weisgraber K.H., Mahley R.W., et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B-48 remnants that is corrected by excess of apolipoprotein E. J. Biol. Chem. 1994, 269:2324-2335.
138. Zhang S., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apoE. Science 1992, 258:468-471.
139. Simons L.A., Dwyer T., Simons J., Bernstein L., Mock P., Poonia N.S., et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987, 65:181-189.
140. Meyer E., Westerveld H.T., de Ruyter-Meijstek F.C., van Greevenbroek M.M.J., Rienks R., van Rijn H.J.M., et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a casecontrol study. Atherosclerosis 1996, 124:221-235.
141. Orth M., Dierkes J., Luley C. Chylomicron remnant concentrations in patients with coronary artery disease. Clin. Chem. Lab. Med. 2003, 41:652-662.
142. Schaefer E.J., Audelin M.C., McNamara J.R., Shah P.K., Taylor T., Daly J.A., et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am. J. Cardiol. 2001, 88:1129-1133.
143. Slyper A.H., Zvereva S., Schectman G., Hoffman R.G., Pleuss J., Walker J.A. Normal postprandial lipemia and chylomicron clearance in offspring of parents with early coronary artery disease. J. Clin. Endocrinol. Metab. 1998, 83:1106-1110.
144. Alipour A., Valdivielso P., Elte J.W., Janssen H.W., Rioja J., van der Meulen N., et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur. J. Clin. Invest. 2012, 42:702-708.
145. Feoli-Fonseca J.C., Lévy E., Godard M., Lambert M. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J. Pediatr. 1998, 133:417-423.
146. Sugandhan S., Khandpur S., Sharma V.K. Familial chylomicronemia syndrome. Pediatr. Dermatol. 2007, 24:323-325.
147. Lone S.W., Imdad A., Billoo A.G. Familial chylomicronemia in a nine months old infant. J. Coll. Physicians Surg. Pak. 2008, 18:655-656.
148. Wilson C.J., Priore O.C., Maggi F., Catapano A.L., Calandra S. Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Ann. Neurol. 2003, 53:807-810.
149. Nakajima K., Takeichi S., Nakajima Y., Fujita M.Q. Pokkuri Death Syndrome; sudden cardiac death cases without coronary atherosclerosis in South Asian young males. Forensic Sci. Int. 2010, 207:6-13.
150. Takeichi S., Nakajima Y., Osawa M., Yukawa N., Saito T., Seto Y., et al. The possible role of remnant-like particles as a risk factor for sudden cardiac death. Int. J. Legal Med. 1997, 110:213-219.
151. Takeichi S., Yukawa N., Nakajima Y., Osawa M., Saito T., Seto Y., et al. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 1999, 42:309-315.
152. Takeichi S., Nakajima Y., Yukawa N., Saito T., Seto Y., Huang X.L., et al. Plasma triglyceride-rich lipoprotein remnants as a risk factor of Pokkuri disease. Leg. Med. 2001, 3:84-94.
153. Ohara N., Takeichi S., Naito Y., Nakajima Y., Yukawa N., Nakano T., et al. Remnant-like particles from subjects who died of coronary artery disease suppress NO synthetase activity and attenuate endotherium-dependent vasorelaxation. Clin. Chim. Acta 2003, 338:151-156.
154. Takeichi S., Nakajima Y., Yukawa N., Fujita M.Q., Saito T., Satoh F., et al. Validity of plasma remnant lipoproteins as surrogate markers of antemortem levels in case of sudden coronary death. Clin. Chim. Acta 2004, 343:93-103.
155. Takeichi S., Nakajima K., Nakajima Y., Fujita M.Q. Pathological characteristics of Pokkuri Death Syndrome; narrow circumferences of the coronary arteries in Pokkuri Death Syndrome cases. Atherosclerosis 2008, 200:80-82.
156. Nakajima K., Nakajima Y., Takeichi S., Fujita M.Q. ApoB-100 carrying lipoprotein, but not apoB-48, is the major subset of proatherogenic remnant-like lipoprotein particles detected in plasma of sudden cardiac death cases. Atherosclerosis 2007, 194:473-482.
157. Nakajima K., Nakajima Y., Takeichi S., Fujita M.Q. Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases. Atherosclerosis 2008, 198:237-246.
158. Oi K., Shimokawa H., Hiroki J., Uwatoku T., Abe K., Matsumoto Y., et al. Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler. Thromb. Vasc. Biol. 2004, 24:918-922.
159. Rapp J.H., Lespine A., Hamilton R.L., Colyvas N., Chaumeton A.H., Tweedie-Hardman J., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 1994, 14:1767-1774.
160. Guo Q., Avramoglu R.K., Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 2005, 54:689-697.
161. Lamon-Fava S., Diffenderfer M.R., Barrett P.H., Buchsbaum A., Matthan N.R., Lichtenstein A.H., et al. Effects of different doses atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 2007, 48:1746-1753.
162. Ai M., Otokozawa S., Asztalos B.F., Nakajima K., Stein E., Jones P.H., et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am. J. Cardiol. 2008, 101:315-318.
163. Schaefer E.J., McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Ordovas J.M., et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002, 25:989-994.
164. Curtin A., Deegan P., Owens D., Collins P., Johnson A., Tomkin G.H. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol. 1996, 33:205-210.
165. Lewis G.F., Carpentier A., Adeli K., Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 2002, 23:201-229.
166. Haffner S.M., Foster D.M., Kushwaha R.S., Hazzard W.R. Retarded chylomicron apolipoprotein-B catabolism in type 2 (non insulin-dependent) diabetic subjects with lipaemia. Diabetologia 1984, 26:349-354.
167. Mamo J.C., Hirano T., Sainsbury A., Fitzgerald A.K., Redgrave T.G. Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Biochim. Biophys. Acta 1992, 1128:132-138.
168. Duez H., Lamarche B., Uffelman K.D., Valero R., Cohn J.S., Lewis G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1357-1363.
169. Welty F.K., Lichtenstein A.H., Barrett P.H., Dolnikowski G.G., Schaefer E.J. Human apolipoprotein (Apo) B-48 and Apo B-100 kinetics with stable isotopes. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2966-2974.
170. Bilz S., Wagner S., Schmitz M., Bedynek A., Keller U., Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J. Lipid Res. 2004, 45:174-185.
171. Watts G.F., Barrett P.H., Ji J., Serone A.P., Chan D.C., Croft K.D., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
172. Forster L.F., Stewart G., Bedford D., Stewart J.P., Rogers E., Shepherd J., et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002, 164:129-145.
173. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fiévet C., Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999, 452:160-164.
174. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 2001, 107:1423-1432.
175. Aguilar-Salinas C.A., Hugh P., Barrett R., Pulai J., Zhu X.L., Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler. Thromb. Vasc. Biol. 1997, 17:72-82.
176. Cuchel M., Schaefer E.J., Millar J.S., Jones P.J., Dolnikowski G.G., Vergani C., et al. Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1910-1917.
177. Chan D.C., Barrett P.H., Watts G.F. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr. Opin. Lipidol. 2006, 17:28-36.
178. Watts G.F., Chan D.C., Barrett P.H., O'Neill F.H., Thompson G.R. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int. J. Obes. Relat. Metab. Disord. 2003, 27:862-865.
179. Lally S., Tan C.Y., Owens D., Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006, 49:1008-1016.
180. Parhofer K.G., Laubach E., Barrett P.H. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid Res. 2003, 44:1192-1198.
181. Watts G.F., Barrett P.H., Marais A.D., Dane-Stewart C.A., Martins I.J., Dimmitt S.B., et al. Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. Atherosclerosis 2001, 157:519-523.
182. The FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366:1849-1861.
183. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
184. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
185. Chan D.C., Watts G.F., Ooi E.M.M., Ji J., Johnson A.G., Barrettet P.H.R. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1831-1837.
186. Beishuizen E.D., Jamsma J.T., Jukema J.W., van de Ree M.A., van der Vijver J.C.M., Meinders A.E., et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28:1668-1674.
187. van de Ree M.A., Huisman M.V., De Man F.H., van der Vijver J.C.M., Meinders A.E., Blauw G.J. Impaired endothelium-dependent vasodilatation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc. Res. 2001, 52:299-305.
188. van Venrooij F.V., van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., Banga J.D. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002, 25:1211-1216.
189. Hamilton S.J., Chew G.T., Davis T.M.E., Watts G.F. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin treated type 2 diabetic patients. Clin. Sci. 2010, 118:607-615.
190. Ryan K.E., McCance D.R., Powell L., McMahon R., Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007, 194:123-130.
191. Valdivielso P., Rioja J., García-Arias C., Sánchez-Chaparro M.A., González-Santos P. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovasc. Diabetol. 2009, 8:8-13.
192. Lamon-Fava S., Diffenderfer M.R., Barrett P.H.R., et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 2007, 48:1746-1753.
193. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
194. Park Y., Harris W.S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res. 2003, 44:455-463.
195. Hamazaki K., Itomura M., Huan M., Nishizawa H., Watanabe S., Hamazaki T., et al. n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans. Lipids 2003, 38:353-358.
196. Hogue J., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J. Lipid Res. 2007, 48:1336-1342.
197. Ando M., Sanaka T., Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J. Am. Soc. Nephrol. 1999, 10:2177-2184.
198. Olivecrona G., Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CIIdeficient chylomicrons. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1545-1549.
199. Taskinen M.R., Nikkila E.A. High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man-evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. Clin. Chim. Acta 1981, 112:325-332.
200. Merkel M., Heeren J., Dudeck W., Rinninger F., Radner H., Breslow J.L., et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J. Biol. Chem. 2002, 277:7405-7411.
201. Heeren J., Niemeier A., Merkel M., Beisiegel U. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. J. Mol. Med. 2002, 80:576-584.
202. Milosavljevic D., Kontush A., Griglio S., Le Naour G., Thillet J., Chapman M.J. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass. Biochim. Biophys. Acta 2003, 1631:51-60.
203. Babaev V.R., Fazio S., Gleaves L.A., Carter K.J., Semenkovich C.F., Linton M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 1999, 103:1697-1705.
204. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135.
205. Clee S.M., Bissada N., Miao F., Miao L., Marais A.D., Henderson H.E., et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J. Lipid Res. 2000, 41:521-531.
206. Nierman M.C., Rip J., Twisk J., Meulenberg J.J.M., Kastelein J.J.P., Stroes E.S.G., Kuivenhoven J.A. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice (Review). Neth. J. Med. 2005, 63:14-19.
207. Excoffon K.J., Liu G., Miao L., Wilson J.E., McManus B.M., Semenkovich C.F., et al. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2532-2539.
208. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 2000, 24:257-261.
209. Wittrup H.H., Tybjaerg-Hansen A., Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999, 99:2901-2907.
210. Van Bockxmeer F.M., Liu Q., Mamotte C., Burke V., Taylor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001, 157:123-129.
211. Gagné S.E., Larson M.G., Pimstone S.N., Schaefer E.J., Kastelein J.J., Wilson P.W., et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin. Genet. 1999, 55:450-454.
212. Chen W., Srinivasan S.R., Elkasabany A., Ellsworth D.L., Boerwinkle E., Berenson G.S. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis 2001, 159:367-373.
213. Clee S.M., Loubser O., Collins J., Kastelein J.J., Hayden M.R. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin. Genet. 2001, 60:293-300.
214. Myllykangas L., Polvikoski T., Sulkava R., Notkola I.L., Rastas S., Verkkoniemi A., et al. Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann. Med. 2001, 33:486-492.
215. Shimo-Nakanishi Y., Urabe T., Hattori N., Watanabe Y., Nagao T., Yokochi M., et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 2001, 32:1481-1486.
216. Rip J., Nierman M.C., Sierts J.A., Petersen W., Van den Oever K., Van Raalte D., et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum. Gene Ther. 2005, 16:1276-1286.
217. Carpentier A.C., Frisch F., Labbé S.M., Gagnon R., de Wal J., Greentree S., et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. Clin. Endocrinol. Metab. 2012, 97:1635-1644.
218. Gaudet D., Méthot J., Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 2012, 23:310-320.